Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C019199 plus Sintilimab in advanced solid tumors
NCT06220318Phase 2Active, not recruiting
- Sponsor
- Haixi New Pharma
- Start
- Jul 2023
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of C019199 in solid tumor, sponsored by Haixi New Pharma. Primary endpoints: Dose-Limiting Toxicity at 21 days, Objective Response Rate and 1 more. Started Jul 2023; status: active, not recruiting.
02
Drugs
C019199
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06220318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06220318.